{"id":63813,"date":"2026-04-23T21:45:07","date_gmt":"2026-04-23T13:45:07","guid":{"rendered":"https:\/\/flcube.com\/?p=63813"},"modified":"2026-04-23T21:45:08","modified_gmt":"2026-04-23T13:45:08","slug":"fda-approves-sanofi-regenerons-dupilumab-for-pediatric-chronic-spontaneous-urticaria-in-children-aged-2-11-years","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63813","title":{"rendered":"FDA Approves Sanofi-Regeneron&#8217;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years"},"content":{"rendered":"\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted approval to <strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)<\/strong> and <strong>Regeneron (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>)<\/strong> for <strong>dupilumab<\/strong>, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of <strong>pediatric patients aged 2 to 11 years<\/strong> with <strong>chronic spontaneous urticaria (CSU)<\/strong> who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy&#8217;s indication into younger patient populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-summary\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New pediatric indication<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Dupilumab (monoclonal antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic spontaneous urticaria (CSU) in patients aged 2\u201311 years<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Symptomatic despite H1 antihistamine treatment<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>Week of April 22, 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Previously approved in EU and multiple countries for same pediatric indication<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Commercial launch and physician education initiatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism-of-action\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Target:<\/strong> Dual inhibition of <strong>interleukin-4 (IL-4)<\/strong> and <strong>interleukin-13 (IL-13)<\/strong>, key drivers of type 2 inflammation<\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> Monoclonal antibody (mAb)<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Subcutaneous injection<\/li>\n\n\n\n<li><strong>Clinical Need:<\/strong> Addresses unmet medical need in pediatric CSU patients refractory to standard antihistamine therapy<\/li>\n\n\n\n<li><strong>Global Recognition:<\/strong> Already approved in the <strong>European Union<\/strong> and <strong>multiple international markets<\/strong> for the same pediatric indication<\/li>\n\n\n\n<li><strong>Existing Indications:<\/strong> Dupilumab is already approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis across various age groups<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-assessment\">Market Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>Estimated 15,000\u201320,000 pediatric CSU patients aged 2\u201311 in the U.S. refractory to antihistamines<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Potential annual revenue contribution of $180\u2013250 million by 2028<\/td><\/tr><tr><td><strong>Competitive Advantage<\/strong><\/td><td>First and only biologic approved for pediatric CSU in this age group<\/td><\/tr><tr><td><strong>Pricing Strategy<\/strong><\/td><td>Expected to follow existing dupilumab pricing framework (~$40,000 annually per patient)<\/td><\/tr><tr><td><strong>Reimbursement Outlook<\/strong><\/td><td>Favorable coverage expected given established safety profile and unmet need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>This approval represents a strategic milestone for the Sanofi-Regeneron partnership, further solidifying dupilumab&#8217;s position as a leading immunology franchise. By expanding into pediatric CSU, the companies are addressing a significant unmet medical need while extending the drug&#8217;s lifecycle and market reach.<\/p>\n\n\n\n<p>The alignment between U.S. and European regulatory decisions demonstrates global consensus on dupilumab&#8217;s benefit-risk profile in pediatric CSU. This harmonization simplifies global development and commercial strategies for the partners.<\/p>\n\n\n\n<p>For Sanofi and Regeneron, this approval reinforces their leadership in type 2 inflammatory diseases and provides additional growth momentum for the dupilumab franchise, which generated approximately $9.2 billion in global sales in 2025.<\/p>\n\n\n\n<p>The approval also highlights the FDA&#8217;s increasing willingness to approve innovative therapies for pediatric rare and chronic conditions, particularly when robust clinical data demonstrates meaningful clinical benefit over existing standard-of-care treatments.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market opportunities, revenue projections, and regulatory developments. Actual results may differ due to competitive dynamics, reimbursement challenges, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,1166,867,68,15,1426,147],"class_list":["post-63813","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-nasdaq-regn","tag-nasdaq-sny","tag-pediatric-drugs","tag-product-approvals","tag-regeneron-pharmaceuticals","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Approves Sanofi-Regeneron&#039;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy&#039;s indication into younger patient populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63813\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Sanofi-Regeneron&#039;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy&#039;s indication into younger patient populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63813\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T13:45:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T13:45:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Approves Sanofi-Regeneron&#8217;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years\",\"datePublished\":\"2026-04-23T13:45:07+00:00\",\"dateModified\":\"2026-04-23T13:45:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2302.webp\",\"keywords\":[\"Auto-immune\",\"NASDAQ: REGN\",\"NASDAQ: SNY\",\"Pediatric drugs\",\"Product approvals\",\"Regeneron Pharmaceuticals\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63813#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63813\",\"name\":\"FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2302.webp\",\"datePublished\":\"2026-04-23T13:45:07+00:00\",\"dateModified\":\"2026-04-23T13:45:08+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy's indication into younger patient populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63813\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2302.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63813#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Sanofi-Regeneron&#8217;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy's indication into younger patient populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63813","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years","og_description":"The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy's indication into younger patient populations.","og_url":"https:\/\/flcube.com\/?p=63813","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-23T13:45:07+00:00","article_modified_time":"2026-04-23T13:45:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63813#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63813"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Approves Sanofi-Regeneron&#8217;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years","datePublished":"2026-04-23T13:45:07+00:00","dateModified":"2026-04-23T13:45:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63813"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63813#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp","keywords":["Auto-immune","NASDAQ: REGN","NASDAQ: SNY","Pediatric drugs","Product approvals","Regeneron Pharmaceuticals","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63813#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63813","url":"https:\/\/flcube.com\/?p=63813","name":"FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63813#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63813#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp","datePublished":"2026-04-23T13:45:07+00:00","dateModified":"2026-04-23T13:45:08+00:00","description":"The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) for dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine (H1AH) treatment. This marks a significant expansion of the therapy's indication into younger patient populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63813#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63813"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63813#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp","width":1080,"height":608,"caption":"FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63813#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Sanofi-Regeneron&#8217;s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2\u201311 Years"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63813"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63813\/revisions"}],"predecessor-version":[{"id":63818,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63813\/revisions\/63818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63817"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}